UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Celltrion unveils clinical results of Remsima SC in treating IBD
Celltrion said that is has presented the phase 1, part 2 trial results for ...
by Lee Han-soo
|
2019-10-22 17:00
라인
Biogen, Samsung Bioepis to present biosimilar data at EU conference
Biogen and Samsung Bioepis said that they plan to present new real-world da...
by Lee Han-soo
|
2019-10-22 11:31
라인
Medytox exported ₩3.3 billion worth of unqualified BTX
The Ministry of Food and Drug Safety ordered Medytox to recall and discard ...
by Jeong Sae-im
|
2019-10-18 16:02
라인
State organs squandered ₩8.2 billion; failed to spot Invossa problem
The government invested 8.21 billion won ($6.9 million) in healthcare-relat...
by Kwak Sung-sun
|
2019-10-16 15:06
라인
[Exclusive] Samsung admits it failed to develop Rituxan biosimilar
The Samsung Group has admitted that a Samsung-affiliated company failed to ...
by Jeong Sae-im
|
2019-10-16 14:16
라인
Kolon Life Science shares surge after TissueGene’s survival
Shares of Kolon Life Science shot up after the regulator decided to delay t...
by Jeong Sae-im
|
2019-10-14 18:01
라인
HLB merges with Elevar to own rivoceranib rights
HLB said it would merge with its subsidiary Elevar, a U.S.-based developer ...
by Jeong Sae-im
|
2019-10-14 14:43
라인
Samsung Bioepis to present data of Etanercept biosimilar in Europe
Samsung Bioepis said that it has unveiled the real-world data (RWD) of Bene...
by Lee Han-soo
|
2019-10-10 11:31
라인
‘Kosdaq firms listed for exceptional tech need special monitoring’
About 80 percent of companies listed on the Kosdaq stock market using the r...
by Jeong Sae-im
|
2019-10-07 15:51
라인
SK Plasma launches human immunoglobulin in Brazil
SK Plasma said that it has won the $20-million bid to supply LIV-Gamma, a h...
by Lee Han-soo
|
2019-10-07 11:23
라인
‘New law to support advanced biopharmaceuticals, ensure safety’
The Ministry of Food and Drug Safety is preparing to implement the “Act on ...
by Lee Hye-seon
|
2019-10-04 15:18
라인
Samsung execs pass buck to biotech subsidiaries for destroying evidence
Samsung executives said Samsung BioLogics and Samsung Bioepis workers were ...
by Jeong Sae-im
|
2019-10-04 11:42
라인
Samsung Bioepis releases P3 results of Bevacizumab biosimilar in EU
Samsung Bioepis has presented the results of phase 3 study clinical evaluat...
by Lee Han-soo
|
2019-09-27 11:37
라인
‘Samsung BioLogics destroyed evidence to hide accounting fraud for months’
Executives of Samsung BioLogics and affiliated companies claimed that they ...
by Jeong Sae-im
|
2019-09-26 15:24
라인
Celltrion to start marketing Herzuma in Middle East
Celltrion Healthcare said that it won the bid to sell Herzuma, an anticance...
by Lee Han-soo
|
2019-09-26 15:02
라인
Helixmith blames hospital for absurd drug mix-up
Helixmith used to be one of the promising biotech firms with its market cap...
by Jeong Sae-im
|
2019-09-25 13:42
라인
Court rejects Kolon’s appeal over Invossa license revocation
A Seoul court turned down Kolon Life Science’s appeal for stopping the gove...
by Jeong Sae-im
|
2019-09-25 11:18
라인
FDA recommends Kolon to remanufacture Invossa’s second fluid
The U.S. Food and Drug Administration has recommended Kolon TissueGene to r...
by Jeong Sae-im
|
2019-09-23 15:32
라인
Dong-A ST's Aranesp biosimilar gets nod in Japan
Dong-A ST said that Sanwa Kagaku Kenkyusho (SKK), its Japanese partner, has...
by Lee Han-soo
|
2019-09-23 15:31
라인
Biotech startups seek IPO via ‘growth potential exception’ policy
An increasing number of biotech companies are eyeing on the Korea Exchange’...
by Jeong Sae-im
|
2019-09-17 11:26
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top